NLRP3 and non-small cell lung carcinoma: CD3+C5AR1+, CD3+CLEC4A+ and CD3+NLRP3+ MFI also significantly discriminated between early-stage NSCLC patients and healthy volunteers with an area under the ROC curve of 0.74 (p < 0.0001), 0.69 (p = 0.0006) and 0.76 (p < 0.0001) respectively (Fig. 1d).